SILDENAFIL RESEARCH LIQUIDAdmin
Sildenafil is a PDE type 5 inhibitor (PDE5Is), a class of drugs used to prolong the physiological effects of nitric oxide/cyclic guanosine monophosphate (NO/cGMP) signaling in tissues by stopping cGMP degradation.
Although sildenafil was originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension observed during clinical trials with research animals.
PHARMACOLOGY OF SILDENAFIL
Sildenafil works by inhibiting an enzyme called cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5.
cGMP is responsible for relaxing the smooth muscles in the blood vessels that feed blood to the corpus cavernosum, the spongy tissue in the penis that becomes engorged with blood during an erection.
By inhibiting PDE5, sildenafil keeps cGMP from breaking down, meaning that more of it is available to relax the blood vessels and promote an erection. But that does not indicate that sildenafil instantly causes an erection.
SIDE EFFECTS OF SILDENAFIL
Common side effects observed in research animals include:
- Dyspepsia of mild or moderate severity
- Myalgia that occurs frequently
- An abnormal vision
- Headache and vasodilatation
- Hypotension and dizziness
When searching for research liquids online, it is paramount to buy from a trusted laboratory to ensure the integrity of your research.
Loti Labs offers affordable prices that come with quality control reports. We have in-depth customer support and a generous return policy when you buy sildenafil for sale.
Visit our website or contact us today to buy sildenafil online.
- Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47-52. [Article]
- Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999 Jan;33(1):273-82. [Article]
- Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005 Nov 8;112(19):2980-5. [Article]
- Unegbu C, Noje C, Coulson JD, Segal JB, Romer L: Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors. Pediatrics. 2017 Mar;139(3). pii: peds.2016-1450. doi: 10.1542/peds.2016-1450. [Article]
- Gong B, Ma M, Xie W, Yang X, Huang Y, Sun T, Luo Y, Huang J: Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017 Oct;49(10):1731-1740. doi: 10.1007/s11255-017-1644-5. Epub 2017 Jul 24. [Article]
- Goldstein I, Burnett AL, Rosen RC, Park PW, Stecher VJ: The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. Sex Med Rev. 2019 Jan;7(1):115-128. doi: 10.1016/j.sxmr.2018.06.005. Epub 2018 Oct 6. [Article]